Regeneron Pharmaceuticals, Inc. Earnings Dividend

Regeneron Pharmaceuticals, Inc.’s revenue jumped 19.04% since last year same period to $3605.4Mn in the Q1 2026. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -7.18% fall in its revenue since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit fell -10.08% since last year same period to $727.2Mn in the Q1 2026. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -13.9% fall in its net profits since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit margin fell -24.46% since last year same period to 20.17% in the Q1 2026. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -7.24% fall in its net profit margins since last 3-months.

Regeneron Pharmaceuticals, Inc.’s price-to-earnings ratio after this Q1 2026 earnings stands at 17.45.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 9.16 - a -12.93% fall from last quarter’s estimates.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 9.16.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) jumped 15.21% since last year same period to 9.47 in the Q1 2026. This indicates that the Regeneron Pharmaceuticals, Inc. has generated 15.21% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Regeneron Pharmaceuticals, Inc.’s return on assets (ROA) stands at 0.06.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Regeneron Pharmaceuticals, Inc.’s return on equity (ROE) stands at 0.15.

Regeneron Pharmaceuticals, Inc. declared 0.94 dividend per share during the earnings announcement for Q1 2026.